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Abstract 
Cerebrospinal fluid (CSF) biomarkers can reflect different aspects of the pathophysiology of 
relapsing-remitting multiple sclerosis (RRMS). Understanding the impact of different disease 
modifying therapies on the CSF biomarker profile may increase their implementation in 
clinical practice and their appropriateness for monitoring treatment efficacy. The present 
study investigated the influence of first-line (interferon beta) and second-line (natalizumab) 
therapies on seven CSF biomarkers in RRMS and their correlation with clinical and 
radiological outcomes. 
We included 59 RRMS patients and 39 healthy controls. The concentrations of C-X-C motif 
chemokine 13 (CXCL13), C-C motif chemokine ligand 2 (CCL2), chitinase-3-like protein 1 
(CHI3L1), glial fibrillary acidic protein (GFAP), neurofilament light protein (NFL), and 
neurogranin (NGRN) were determined by ELISA, and chitotriosidase (CHIT1) was analyzed 
by spectrofluorometry.  
RRMS patients had higher levels of NFL, CXCL13, CHI3L1, and CHIT1 than controls 
(p<0.001). Subgroup analysis revealed higher NFL, CXCL13 and CHIT1 levels in patients 
treated with first-line therapy compared to second-line therapy (p=0.008, p=0.001 and 
p=0.026, respectively). NFL and CHIT1 levels correlated with relapse status, and NFL and 
CXCL13 levels correlated with the formation of new MRI lesions. Furthermore, we found an 
association between inflammatory and degenerative biomarkers.  
The results indicate that CSF levels of NFL, CXCL13, CHI3L1, and CHIT1 correlate with the 
clinical and/or radiological disease activity, providing additional dimensions in the assessment 
of treatment efficacy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Accumulating evidence suggests that, in relapsing-remitting multiple sclerosis (RRMS), early 
signs of CNS degeneration are dependent on inflammatory activity (Malmestrom et al., 2003, 
Lycke et al., 1998, Gunnarsson et al., 2011). The levels of several cerebrospinal fluid (CSF) 
biomarkers seem to reflect disease activity, and CSF levels decrease towards normality during 
intervention with disease modifying therapies (DMTs) (Gunnarsson et al., 2011, Kuhle et al., 
2015a, Khademi et al., 2011, Conductier et al., 2010, Comabella et al., 2010, Malmestrom et 
al., 2014, Verbeek et al., 2010, Lycke et al., 1998, Axelsson et al., 2014, Franciotta et al., 
2001, Axelsson et al., 2011, Sellebjerg et al., 2009, Olsson et al., 2012). Previous 
investigations of CSF biomarkers revealed altered immune cell (Sospedra and Martin, 2005) 
and protein profiles, reflecting different aspects of the immunopathogenesis of MS (Axelsson 
et al., 2011, Malmestrom et al., 2003, Sellebjerg et al., 2009).  
Neurofilament light protein (NFL) is a major component of the cytoskeleton of the axon, and 
elevated levels of NFL in the CSF of MS patients indicate ongoing neuro-axonal degeneration 
(Malmestrom et al., 2003, Lycke et al., 1998). NFL levels are increased in the CSF during all 
stages of MS, with the highest levels following acute relapses (Malmestrom et al., 2003) or 
during contrast enhancement of lesions on MRI (Axelsson et al., 2014). DMTs reduce the 
CSF levels of NFL (Gunnarsson et al., 2011, Kuhle et al., 2015a, Axelsson et al., 2014). 
Chitinase-3-like protein 1 (CHI3L1, also known as YKL-40) is expressed by microglia, 
macrophages, epithelial cells, and astrocytes and is involved in the pathogenesis of chronic 
autoimmune disorders (Bonneh-Barkay et al., 2012). High CSF levels of CHI3L1 have been 
associated with disability progression and, together with NFL, are higher in patients with 
shorter time to conversion to MS from a clinically isolated syndrome (CIS) (Comabella et al., 
2010, Martinez et al., 2015). CSF CHI3L1 levels are reduced by DMTs (Malmestrom et al., 
2014). Glial fibrillary acidic protein (GFAP) is also expressed by astrocytes. The 
concentration of GFAP in the CSF is thought to reflect astrogliosis, and increased 
concentrations of GFAP and CHI3L1 have been associated with the progression of disability 
in MS (Axelsson et al., 2011, Malmestrom et al., 2003) (Martinez et al., 2015). 
Chitotriosidase (also known as chitinase 1, CHIT1) is a marker of microglial activation 
(Olsson et al., 2012, Verbeek et al., 2010). Elevated CHIT1 levels are associated with 
conversion to MS in patients with CIS (Mollgaard et al., 2016). Treatment with natalizumab 
reduces CHIT1 levels (Olsson et al., 2012). 
C-X-C motif chemokine 13 (CXCL13) is a B-cell chemokine. The concentration of CXCL13 
in CSF is increased in patients with active MS and in patients converting from CIS to MS 
(Khademi et al., 2011). CXCL13 levels are reduced by natalizumab treatment (Sellebjerg et 
al., 2009). 
C-C motif chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-
1 (MCP-1), is an important chemokine for the recruitment of monocytes and macrophages to 
the CNS. The CNS levels of CCL2 are reduced during increased disease activity in MS 
(Franciotta et al., 2001, Mahad and Ransohoff, 2003).  
Neurogranin (NGRN) is a postsynaptic protein enriched in dendritic spines. Elevated levels of 
NRGN have been found in subjects with mild cognitive impairment (MCI) and Alzheimer’s 
disease (AD) (Thorsell et al., 2010, Kester et al., 2015). In CSF, NGRN is a marker of 
synaptic integrity and its levels are influenced by neurodegeneration (Portelius et al., 2015). 
In the present study, we explored the possible relationships between these CSF biomarkers of 
inflammation and degeneration in RRMS compared to healthy controls, as well as the 
influence of different DMTs on biomarker levels. A better understanding of the relationships 
between these biomarkers could lead to their implementation in clinical practice and treatment 
monitoring. 
 
Material and methods 
Patients and healthy controls  
Patients with RRMS fulfilling the revised McDonald criteria (Polman et al., 2011) who had an 
indication to switch therapies because of breakthrough disease activity (n=40), 
tolerability/adverse events (n=2), or risk of progressive multifocal leukoencephalopathy 
(PML) due to JC virus antibody positivity during natalizumab therapy (n=17) were 
consecutively enrolled in the study at the MS centers of Sahlgrenska University Hospital, 
Gothenburg (n=17), and Karolinska University Hospital, Stockholm, Sweden (n=42). A total 
of 59 patients were enrolled, 7 were treatment naïve (n=4) or without DMT for one year or 
more, 33 were on first-line (interferon beta) and 19 were on second-line treatment 
(natalizumab) for at least 1 year before the study. 
Thirty-nine blood donors and university students served as healthy controls. None of the 
controls had any neurological signs or a history of neurological disease. The demographic and 
clinical characteristics of the patients and controls are presented in Table 1.  
 
Clinical assessments and MRI 
Patients underwent a clinical neurological examination, MRI, and lumbar puncture at one 
time point (Table 1). A relapse was defined as an episode of neurological disturbance lasting 
for at least 24 h (McDonald et al., 2001). The neurological examinations were performed by 
trained neurologists, disability measured using the Expanded Disability Status Scale (EDSS) 
(Kurtzke, 1983), and disease severity with the Multiple Sclerosis Severity Score (MSSS) 
(Roxburgh et al., 2005). The MRI scans of the brain and cervical column were performed 
with 1.5 or 3.0 Tesla machines using a 3 mm slice thickness. A standard protocol for MS was 
applied with T1- and T2-weighted sequences, FLAIR, and T1 following a standard dose of 
intravenous gadolinium (Gd) contrast. Because Gd-enhancement on MRI appears in the 
majority of cases during a period of 6 weeks, mean 3.07 weeks (Cotton et al., 2003) we 
choose to include only MRI performed 6 weeks before or after lumbar puncture in order to 
evaluate correlation between MRI measures and CSF biomarker concentrations. New disease 
activity on MRI compared to a previous MRI was defined as a new Gd-enhanced lesion or 
new or enlarged T2 lesion. 
 
Blood tests and CSF sampling 
Peripheral blood and CSF were sampled at the clinical assessment. The CSF samples were 
handled according to the consensus protocol of the BioMS-EU network for CSF biomarker 
research in MS (Teunissen et al., 2009). Increased concentrations of NFL in CSF were 
expected from relapse onset and approximately 100 days thereafter (Lycke et al., 1998). In 
line with this observation we considered CSF to be obtained during relapse if lumbar puncture 
was performed within this period of time. 
 
Biomarker analysis 
All analyses were performed by board-certified laboratory technicians at the Clinical 
Neurochemistry Laboratory of Sahlgrenska University Hospital according to protocols 
approved by the Swedish Board for Accreditation and Conformity Assessment. CSF NFL 
levels were measured using a sensitive sandwich ELISA method (NF-light® ELISA kit, 
UmanDiagnostics AB, Umeå, Sweden). The intra- and inter-assay coefficients of variation 
were < 10%. The lower limit of quantification (LLoQ) of the assay was 31 pg/mL. GFAP was 
measured in the CSF by ELISA as previously described in detail (Rosengren et al., 1994). The 
LLoQ of the GFAP assay was 16 pg/mL. CSF CXCL13 levels were measured by ELISA 
(Human CXCL13/BLC/BCA-1 Immunoassay, R&D Systems Inc., Abingdon, United 
Kingdom) according to the manufacturer’s instructions. The average intra- and inter-assay 
coefficients of variation were ≤ 10% and the LLoQ was 7.8 pg/mL. CHI3L1 in the CSF was 
analyzed with solid phase sandwich ELISA (Human Chitinase 3-like 1 Quantikine ELISA 
Kit, R&D Systems Inc., Minneapolis, MN). The intra-assay coefficient of variation was < 7% 
and the LLoQ was 8.15 pg/mL. CSF CCL2 levels were also analyzed by solid phase sandwich 
ELISA (Human CCL2/MCP-1 Quantikine ELISA Kit, R&D Systems Inc., Minneapolis, 
MN). The intra- and inter-assay coefficients of variation were ≤ 8% and the LLoQ was 10 
pg/mL. CSF levels of NGRN were measured using an in-house ELISA with the monoclonal 
antibody Ng7 (BioLegend, CA, USA) as the capture antibody and the rabbit anti-NGRN 
antibody (Upstate, MA, USA) as the detecting antibody as described previously (Kvartsberg 
et al., 2015). The LLoQ was 125 pg/mL and the mean intra-assay coefficient of variation 
17%. Chitotriosidase activities in the CSF were measured by an in-house method as described 
previously (Novakova et al., 2016). The LLoQ was 0.2 nkat/L and intra- and inter-assay 
coefficients of variation <10%. CSF samples below the LLoQ were designated as having the 
value of the LLoQ. 
 
Statistical analysis 
Visual inspection of the data and Shapiro-Wilk test of normality did not show a normal 
distribution of the biomarkers; therefore, non-parametric tests were used in this study. The 
Mann-Whitney U test was used for unpaired data and Kruskal-Wallis H test was used to 
analyze several independent samples. Correlations between biomarkers were analyzed by the 
Spearman’s rank correlation test. Multiple regression analysis was performed to test the 
influence of gender, age, EDSS, and MSSS on the biomarkers. Statistical calculations were 
performed in SPSS Statistics 22 software. 
 
Ethics 
 
All patients and controls voluntarily participated in the study and informed consent was 
obtained from all subjects after oral and written information was provided. The regional 
ethical review boards in Uppsala (Dnr 2005:253) and Stockholm (Dnr 2009:2107) approved 
the study.  
 
Results 
The influence of DMTs on biomarker concentrations  
RRMS patients had significantly higher mean CSF levels of NFL, CXCL13, CHI3L1, and 
CHIT1 than controls (p<0.001), but the mean CSF levels of GFAP, CCL2, and NRGN did not 
significantly differ between patients and controls (Table 2). Excluding patients with relapse 
(n=15), the mean CSF levels of NFL, CXCL13, CHI3L1, and CHIT1 were still higher than in 
controls (p=0.002, p<0.001, p=0.005, and p<0.001, respectively). The CSF levels of NFL, 
CXCL13, CHI3L1, and CHIT1 were also significantly higher in untreated patients and in 
patients treated with interferon beta compared to controls (p<0.001). In patients treated with 
natalizumab, only CHI3L1 and CHIT1 were significantly elevated in the CSF compared to 
controls (p=0.001 and p=0.009, respectively). Patients treated with interferon beta had 
significantly higher levels of NFL (p=0.008), CXCL13 (p=0.001), and CHIT1 (p=0.026) than 
those treated with natalizumab. We found no significant difference in the levels of GFAP, 
CHI3L1, NGRN, or CCL2 between patients treated with interferon beta and natalizumab 
(Table 2). 
 
Clinical and radiological characteristics of patients  
Patients without treatment or on first-line treatment had more disease activity than those on 
second-line treatment based on both clinical and radiological measures (Table 3). Within 100 
days (mean 51, range 4-98 days) prior to lumbar puncture, 15 patients without treatment or on 
interferon beta treatment had relapse, and 17 patients had ≥1 Gd-enhanced lesion, whereas no 
patient on natalizumab treatment had relapse and only one of them had one Gd-enhanced 
lesion. The median EDSS and MSSS in the group without treatment, on interferon beta and on 
natalizumab was 1.5 (range 0-5.0) and 2.44 (0.67-9.18), 2.0 (range 0-6.5) and 3.05 (range 
0.17-9.09), and 3.5 (range 0-7.5) and 3.46 (range 0.10-9.13), respectively. We found no 
significant group difference regarding EDSS and MSSS. The mean age was lower in patients 
on interferon beta (36 years, range 19-55 years) compared to patients on natalizumab (42 
years, range 23-59 years, p=0.017), and the disease duration was shorter in patients on 
interferon beta (6 years, range 1-15 years) compared to patients on natalizumab (13 years, 
range 4-23 years, p<0.001). 
 
Relationships between biomarker concentrations and clinical and radiological disease 
activity  
The CSF levels of NFL, CHI3L1, and CHIT1 were higher in patients with a clinical relapse 
(n=15) than patients in clinical remission (p=0.002, p=0.006, and p=0.006, respectively). MRI 
was performed within an average of 23 days (range 1-42 days) before or after lumbar 
puncture (n=25) and compared to a previous MRI performed on average 578 days (range 81-
1294 days) ago. The CSF levels of both NFL and CXCL13 were higher in patients with new 
T2 lesions (n=16) than patients without new T2 lesions (n=9, p=0.007 and p=0.014, 
respectively). When only selecting patients with ≥1 Gd-enhanced lesion (n=7), the levels of 
CXCL13 and NGRN were higher and the levels of CCL2 were lower than in patients without 
Gd-enhanced lesions (n=18, p=0.003, p=0.049 and p=0.029, respectively). Note that no 
differences were observed in NGRN concentrations between patients and controls or between 
first- and second line treatments. 
NFL, CHI3L1, and CHIT1 levels correlated with the clinical relapse rate (r=0.414, p=0.001; 
r=0.358, p=0.0015; and r=0.359, p=0.005, respectively). The level of CHI3L1 was related to 
disability and disease severity based on the EDSS and MSSS, respectively (r=0.274, p=0.036 
and r=0.297, p=0.022). CXCL13 and CCL2 levels correlated with the presence of Gd-
enhanced lesions (r=0.6114, p=0.0001 and r=-0.445, p=0.026, respectively) and with the 
number of Gd-enhanced lesions (r=0.622, p=0.001 and r=-0.505, p=0.010, respectively). 
CXCL13 and NFL were associated with new or enlarged T2 lesions (r=0.502, p=0.011 and 
r=0.555, p=0.004, respectively). No other significant correlations were found between 
biomarker concentrations and clinical or MRI measures. 
 
Biomarker concentrations in patients and healthy controls 
The levels of NFL, GFAP, CHI3L1, and CCL2 were detectable in all patients and controls. 
The levels of CXCL13 were below the LLoQ in 39 controls and 38 patients, the levels of 
CHIT1 were below the LLoQ in 13 controls and 5 patients, and the levels of NGRN were 
below the LLoQ in 14 controls and 21 patients. The mean concentrations of CSF biomarkers 
in healthy controls are presented in Table 2. 
The NFL, GFAP, CHI3L1, and CCL2 levels were age-dependent; therefore, all of the 
correlation analyses were adjusted for age. We found no influence of gender on the analyzed 
biomarkers. Except for a significant relationship between GFAP and CHI3L1 (r=0.552, 
p<0.001), no correlations were found between the analyzed biomarkers in healthy controls. 
We found correlations between biomarkers of inflammation and degeneration in patients 
(Table 4); GFAP correlated with CHI3L1 (r=0.352, p=0.007), NFL correlated with CHI3L1 
(r=0.330, p=0.011), and NFL correlated CHIT1 (r=0.298, p=0.023). CHIT1 correlated with 
two other inflammatory biomarkers, CHI3L1 and CXCL13 (r=0.499, p<0.001 and r=0.298, 
p=0.023, respectively). 
 
Discussion 
The influence of DMTs on the concentrations of seven CSF biomarkers that reflect different 
aspects of the immunopathogenesis of RRMS was explored in this study. We show that B-cell 
regulation (CXCL13), microglial activation (CHIT1, CHI3L1), and axonal damage (NFL) are 
all associated with disease activity in RRMS. Higher levels of these CSF biomarkers were 
observed in patients treated with interferon beta compared to those treated with natalizumab, 
suggesting that the efficacy of therapeutic intervention can be monitored by these biomarkers. 
 
In previous studies, CSF levels of NFL and CXCL13 were shown to be associated with 
disease activity (Malmestrom et al., 2003, Khademi et al., 2011). Thus, NFL and CXCL13 
were increased during relapse (Khademi et al., 2011, Malmestrom et al., 2003) and in the 
presence of contrast enhancing lesions on MRI (Axelsson et al., 2014). In the present study, 
we confirmed the association between NFL and CXCL13 and ongoing clinical and MRI 
activity, but we also showed that these biomarkers correlate with new or enlarged T2 lesions 
in clinically stable patients. Thus, even new or enlarging lesions that do not disrupt the blood-
brain barrier influence the rate of axonal damage. We did not have access to spinal cord MRI 
scans and cannot exclude the possibility that occasional patients could have had enhancing 
cord lesions. However, clinically silent enhancing cord lesions are rare and likely do not 
account for this finding at an aggregate level. 
 
Glial activation occurs during inflammation or damage of the CNS (Bonneh-Barkay et al., 
2012, Eng and Ghirnikar, 1994). In previous studies, increased levels of CHI3L1, CHIT1, and 
GFAP were associated with disease activity (Malmestrom et al., 2014, Olsson et al., 2012) or 
disease progression (Modvig et al., 2013, Martinez et al., 2015, Axelsson et al., 2011, Burman 
et al., 2016, Comabella et al., 2010). Although CHI3L1 correlated with GFAP, only CHI3L1 
correlated with clinical measures of progression (i.e., EDSS) and disease severity (i.e., 
MSSS). However, in previous studies, the correlation between GFAP and EDSS or MSSS 
(Malmestrom et al., 2003, Axelsson et al., 2011) was limited to patients with progressive MS 
(Axelsson et al., 2011) or associated with earlier neurological deterioration and EDSS 
progression (Martinez et al., 2015). Thus, the selection of RRMS patients and the cross-
sectional approach in the present study probably influenced the results. 
 
In contrast to previous studies on MCI and AD (Thorsell et al., 2010, Kester et al., 2015, 
Portelius et al., 2015), NGRN levels were normal in our patients with RRMS. The NGRN 
level increases as the dendritic spines degenerate and is associated with cognitive decline and 
the intensity of synaptic and neuronal degeneration in MCI and AD (Portelius et al., 2015). 
Although axonal damage may become extensive in RRMS, we did not find signs of dendritic 
spine involvement in our patients. 
 
In the present study, we confirmed that natalizumab-treated patients have CSF NFL and 
CXCL13 levels similar to those of healthy controls as previously reported [2, 18], whereas the 
CSF concentration of CHI3L1 (Malmestrom et al., 2014) and CHIT1 (Olsson et al., 2012) do 
not reach normal levels. Thus, a low grade microglial activation seemed to be present even in 
natalizumab-treated RRMS patients who were clinically and radiologically stable. In RRMS 
patients, DMTs decreased CSF concentrations of NFL, CXCL13, CHIT1, and CHI3L1, 
whereas GFAP, NGRN, and CCL2 were unaffected. However, because the CSF 
concentrations of CXCL13 and CHIT1 were frequently below the detection levels of the 
immunoassay, their usefulness for monitoring therapeutic efficacy seemed limited.  
 
In order to correctly interpret CSF biomarker data in relation to disease activity or treatment 
efficacy, certain aspects must be considered. Firstly, the treatment duration may influence 
biomarker levels. Both first- and second-line MS therapies usually achieve an effect on MRI 
and clinical measures after several months of treatment. However, none of our patients were 
on DMTs for less than 1 year. Secondly, some of the biomarkers are age-dependent  e.g. NFL 
(Malmestrom et al., 2003, Lycke et al., 1998, Modvig et al., 2013), GFAP (Malmestrom et al., 
2003, Rosengren et al., 1994), CHI3L1 (Modvig et al., 2013), and CCL-2 (Conductier et al., 
2010)). In the present study all correlations were adjusted for age. Moreover, in the subgroup 
analysis based on the treatment, the group treated with natalizumab was older. However, the 
expected influence of age seemed limited, as significantly lower biomarker levels were found 
in this sub-group. Thirdly, repeated lumbar puncture may not be feasible in some patients due 
to side effects or a fear of the sampling procedure. Therefore, the possibility of clinically 
monitoring therapeutic interventions using CSF biomarkers is limited. Results from analyses 
of CSF biomarkers may essentially contribute to the evaluation of new DMTs in phase II 
trials or in difficult therapeutic decisions for selected patients. However, NFL and CXCL13 
have been reported to be measures of the disease activity of MS in serum (Festa et al., 2009, 
Kuhle et al., 2015b). Thus, the evolution of extremely sensitive assays may make it possible 
to replace CSF with serum or plasma, even for CNS-specific antigens or inflammatory 
disorders of the CNS. Further studies of biomarkers obtained from peripheral blood are highly 
warranted in MS to establish them as biomarkers of disease progression, disease activity, and 
treatment efficacy. 
 
In conclusion, this study showed that CSF biomarkers related to different pathological 
processes involved in MS reflect both disease activity and DMT efficacy. The association 
between neurodegenerative and inflammatory biomarkers confirms the hypothesis regarding 
inflammatory-induced degeneration, at least in the relapsing-remitting phase of the disease 
(Owens, 2003, Stadelmann et al., 2011). The determination of CSF NFL and CHI3L1 levels 
may be useful for measuring treatment efficacy in clinical trials and can also be used to 
monitor DMTs in clinical practice to provide an additional dimension in the assessment of 
treatment efficacy. 
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Tables 
 
Table 1. Baseline demographic and clinical characteristics of patients with relapsing-remitting 
multiple sclerosis and healthy controls. 
  Patients (n=59) Healthy controls (n=39) 
Gender, Men/Women, noa 23/36 25/14 
Mean age, years (range)b 37 (17-59) 34 (21-56) 
Median/Mean EDSS (range) 2.5/2.48 (0-7.5) NA 
Median/Mean MSSS (range) 3.10/3.68 (0.10-9.18) NA 
No treatment 7 NA 
First-line treatment = interferon beta 33 NA 
Second-line treatment = natalizumab 19 NA 
DMT=disease modifying therapy; EDSS=Expanded Disability Status Scale; MSSS=Multiple Sclerosis 
Severity Score; NA not applicable; a p=0.015 patients vs. healthy controls; b p=0.075 patients vs. 
healthy controls 
 
 
 
 
Table 2. Mean concentrations of CSF biomarkers 
  No treatment (n=7) 
First-line treatment 
(n=33) 
Second-line 
treatment (n=19) 
Healthy controls 
(n=39) 
NFL (pg/mL) 1900 (297-7185)a 1319 (165-13237)a,b 707 (161-5852) 364 (78-1287) 
CXCL13 
(pg/mL) 30.9 (7.8-160)a 29 (7.8-226)a,b 8.2 (7.8-16) 7.8 (7.8) 
CHI3L1(ng/mL) 173(78-261)a 132 (50-260)a 120 (44-207)a 85 (24-159) 
GFAP (pg/mL) 561 (344-1414) 519 (169-867) 603 (199-1556) 465 (55-922) 
CCL2 (pg/mL) 410 (242-662) 386 (204-1057) 424(250-639) 373 (250-756) 
NGRN (pg/mL) 206 (125-531) 189 (125-534) 219 (125-414) 241 (125-937) 
CHIT1 (nkat/L) 4.8 (0.2-13.7)a 1.8 (0.2-6.3)a,b 1.2 (0.2-6.2)a 0.4 (0.2-1.6) 
NFL=neurofilament light; CXCL13=C-X-C motif ligand 13; CHI3L1=chitinase-3-like protein 1; 
GFAP=glial fibrillary acidic protein; MCP-1=monocyte chemoattractant protein-1; 
NGRN=neurogranin; CHIT1=chitotriosidase; a p<0.05 patients vs. healthy controls; b p<0.05 first-line 
vs second-line treatment; () range 
 
 
 
 
 
Table 3. Influence from treatment on clinical and MRI outcome in relapsing-remitting 
multiple sclerosis. 
  No treatment First-line treatment Second-line treatment 
Number of Patients 7 33 19 
Gender F/M 5//2 19//14 12//7 
Age, mean (range) 37 (17-49) 35 (19-55) 42 (23-59) 
Disease duration, mean (range) 6.6 (0-18) 6.4 (1-15) 12.7 (4-23) 
EDSS mean/median (range) 2.0/1.5 (0-5.0) 2.17/2.0 (0-6.5) 3.21/3.5 (0-7.5) 
MSSS mean/median (range) 3.08/2.44 (0.67-9-18) 3.83/3.05 (0.17-9.09) 3.65/3.46 (0.10-9.13) 
Relapse, n 3 12 0 
Valid MRI scan, n 7 32 19 
     Patients with Gd+ lesions, n (%) 2 (29) 15 (46) 1 (5) 
     Patients with new or enlarging  
     T2 lesions, n (%) 5 (71) 29 (88) 10 (53) 
F=female; M=male; EDSS=Expanded Disability Status Scale; MSSS=Multiple Sclerosis Severity 
Score; MRI=magnetic resonance imaging; Gd+=gadolinium enhancing 
 
 
 
Table 4. Relationships between biomarkers of inflammation and degeneration 
  NFL GFAP CXCL13 CHI3L1 NGRN CHIT1 CCL2 
NFL               
GFAP 
r=0.109 
(p=0.417)             
CXCL13 
r=0.01 
(p=0.939) 
r=-0.007 
(p=0.96)           
CHI3L1 
r=0.33 
(p=0.011) 
r=0.352 
(p=0.007) 
r=0.242 
(p=0.067)         
NGRN 
r=0.12 
(p=0.369) 
r=0.015 
(p=0.91) 
r=-0.016 
(p=0.903) 
r=-0.084 
(p=0.529)       
CHIT1 
r=0.298 
(p=0.023) 
r=0.161 
(p=0.227) 
r=0.298 
(p=0.023) 
r=0.499 
(p<0.001) 
r=-0.001 
(p=0.995)     
CCL2 
r=-0.016 
(p=0.905) 
r=0.221 
(p=0.096) 
r=-0.13 
(p=0.331) 
r=0.205 
(p=0.122) 
r=-0.146 
(p=0.274) 
r=0.152 
(p=0.254)   
The correlations between CSF biomarker levels are shown. The correlations in bold letters 
were significant (p<0.05). Statistical testing was done by Spearman’s rank correlation 
analysis. All listed correlations and p-values have been corrected for age. r=Spearman’s rho. 
     
 
 
 
Figure legend 
 
Figure 1. Levels of NFL in cerebrospinal fluid in MS patients compared with levels obtained 
in healthy controls. The box indicates the interquartile range (IQR), bar indicates the median, 
and whiskers indicate the 95% CI. Extreme values are marked with open dots (±1.5 x IQR) or 
with asterisks (±3 x IQR). 
Figure 2. Levels of CXCL13 in cerebrospinal fluid in MS patients compared with levels 
obtained in healthy controls. The box indicates the interquartile range (IQR), bar indicates the 
median, and whiskers indicate the 95% CI. Extreme values are marked with open dots (±1.5 x 
IQR) or with asterisks (±3 x IQR). 
Figure 3. Levels of CHI3L1 in cerebrospinal fluid in MS patients compared with levels 
obtained in healthy controls. The box indicates the interquartile range (IQR), bar indicates the 
median, and whiskers indicate the 95% CI. Extreme values are marked with open dots (±1.5 x 
IQR) or with asterisks (±3 x IQR). 
Figure 4. Levels of CHIT1 in cerebrospinal fluid in MS patients compared with levels 
obtained in healthy controls. The box indicates the interquartile range (IQR), bar indicates the 
median, and whiskers indicate the 95% CI. Extreme values are marked with open dots (±1.5 x 
IQR) or with asterisks (±3 x IQR). 
